• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Latest News

ECTRIMS 2019 DAILY REPORT – SATURDAY EDITION

September 14, 2019  

Ofatumumab – new data
Biotin – disappointing results
Natalizumab – 10-year data
Dimethyl fumarate – 10-year results
Declining effect of treatment
Stopping treatment: 2 studies
BTK inhibition
Clinical Tip of the day Read More

TOPICS: MS

ECTRIMS 2019 DAILY REPORT – FRIDAY EDITION

September 13, 2019  

Siponimod in SPMS
Alemtuzumab – 9-year results
Ocrelizumab in PPMS – extension data
Starting and switching DMTs
RIS – Predictors of CIS/MS
Do real-world people enter real-world studies?
Clinical Tip of the day Read More

TOPICS: MS

ECTRIMS Poster Picks – Friday, September 13

September 13, 2019  

Friday, September 13, 2019 – Today’s poster session runs from 12:15-2:15 pm
Here are Steven’s Top poster topics at ECTRIMS for Friday, September 13, 2019. Read More

ECTRIMS 2019 DAILY REPORT – THURSDAY EDITION

September 12, 2019  

Phase III trials in NMOSD
Cladribine and time to SPMS
Hypogammaglobulinemia
Cannabis and cognition
Concussion and MS
Clinical Tip of the day Read More

TOPICS: MS
Previous
74
75
76
77
78
Next

Browse by Topic

  • MS (439)
  • CLINICAL CASES (21)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • AES 2025 (1)
  • EPILEPSY (38)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
  • CNS effects of Wegovy (semaglutide) posted on February 28, 2023
  • Ultomiris (ravulizumab) now publicly reimbursed in gMG posted on April 7, 2026
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions